Abstract:

Objective To explore the treatment measures for patients suffering from novel coronavirus pneumonia disease (hereinafter referred to as “COVID-19”) with cardiovascular complications. Methods Clinical data of 155 patients with COVID-19 were collected, therapies and medications of such patients were analyzed, and clinical therapies for 21 patients with cardiovascular complications were analyzed. Results The single-center incidence of patients with COVID-19 complicated with cardiovascular complications hit 13.5%, the number of patients with hypertension was greater (95.2%), elderly patients with COVID-19 had higher incidence of complicating cardiovascular diseases (38.5%), incidence of acute cardiovascular events during hospital stay was 4.76%. No adverse drug reactions were observed in the application of conventional cardiovascular drugs during the treatment. Critically type COVID-19 patients had high incidence of cardiovascular events during the hospital stay, one case was found to suffer from the drop of blood pressure in the course of plasma exchange therapy. The symptom was relieved by elevated blood pressure treatment, 134 patients who had no cardiovascular complications, two patients experienced hvpertension during the process of pneumonia treatment. Conclusion Potentially induced adverse events should be noted while treating COVID-19 patients. While generic medications and therapies are known to be basically safe and effective for common type of COVID-19 patients with cardiovascular complications, the interactions may potentially take place in critically ill patients with inflammatory cytokine storm and underlying cardiovascular conditions.

Key words: COVID-19, cardiovascular disease, drug therapy, adverse drug reaction